Search
Curis Inc
CRISAdd to Watchlist
5.033USD
+0.073+1.47%
Close 07-31 16:00（ET）Quotes delayed by 15 min
10.06MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Curis Inc is 8.00, ranking 171 out of 385 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 20.00 and a low of 5.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
280.000
Target Price
+5522.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Curis Inc
CRIS
4
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Curis Inc's expected revenue for the next quarter?
Curis Inc's expected revenue is 1.00M.
What is Curis Inc's price target?
Analysts forecast that Curis Inc's price target is USD 17.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 5.00.
How have Curis IncCRIS's recent earnings per share performed?
The market expectation was USD -24.99, while Curis IncCRIS's earnings per share (EPS) for the previous quarter was USD 24.54. EPS for the next quarter is expected at USD -7.47.
What is the analyst rating for Curis Inc?
Based on the ratings of Curis Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.